Published in Arch Virol on January 01, 1989
Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection. Antimicrob Agents Chemother (1992) 1.41
Intranasal pirodavir (R77,975) treatment of rhinovirus colds. Antimicrob Agents Chemother (1995) 1.18
Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses. Antimicrob Agents Chemother (2005) 1.16
Virus receptors: implications for pathogenesis and the design of antiviral agents. Clin Microbiol Rev (1995) 1.07
Spectrum of activity of soluble intercellular adhesion molecule-1 against rhinovirus reference strains and field isolates. Antimicrob Agents Chemother (1994) 0.94
Efficacy of oral WIN 54954 for prophylaxis of experimental rhinovirus infection. Antimicrob Agents Chemother (1993) 0.89
In vitro selection of human rhinovirus relatively resistant to soluble intercellular adhesion molecule-1. Antimicrob Agents Chemother (1994) 0.87
Pathogenicity for humans of human rhinovirus type 2 mutants resistant to or dependent on chalcone Ro 09-0410. Antimicrob Agents Chemother (1990) 0.84
Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ (1995) 9.26
Psychological stress and susceptibility to the common cold. N Engl J Med (1991) 6.84
Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature (1990) 5.70
A comparison of live and killed influenza-virus vaccines. Report to the Medical Research Council's Committee on Influenza and other Respiratory Virus Vaccines. Lancet (1968) 4.66
Experimental parvoviral infection in humans. J Infect Dis (1985) 4.62
Undescribed toxin in pseudomembranous colitis. Br Med J (1977) 4.31
Trials of Live Influenza Vaccine in the Royal Air Force. Br Med J (1962) 4.06
Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J Mol Biol (1994) 3.85
Inhibition of haemaggregation by lepromin and other mycobacterial substances. Nature (1967) 3.84
Work of a district ethical committee. Br Med J (1979) 3.64
The time course of the immune response to experimental coronavirus infection of man. Epidemiol Infect (1990) 3.12
The relationship between upper respiratory infections and hospital admissions for asthma: a time-trend analysis. Am J Respir Crit Care Med (1996) 3.10
Inhibition of respiratory virus infection by locally applied interferon. Lancet (1973) 3.02
Use of polymerase chain reaction for diagnosis of picornavirus infection in subjects with and without respiratory symptoms. J Clin Microbiol (1993) 3.01
Determination of itraconazole in plasma and animal tissues by high-performance liquid chromatography. J Chromatogr (1987) 2.76
Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother (1988) 2.73
Role of viruses in febrile convulsions. Arch Dis Child (1979) 2.72
Neuraminidase and resistance to vaccination with live influenza A2 Hong Kong vaccines. J Hyg (Lond) (1971) 2.70
Investigetion into the attenuation of influenza viruses by serial passage. Br Med J (1968) 2.67
Immunogenicity and acceptability of a human diploid-cell culture rabies vaccine in volunteers. Lancet (1975) 2.61
Amplification of rhinovirus specific nucleic acids from clinical samples using the polymerase chain reaction. J Med Virol (1989) 2.47
Antiviral activity in milk of possible clinical importance. Lancet (1976) 2.47
Serological studies on infections by respiratory viruses of the inhabitants of Tristan da Cunha. J Hyg (Lond) (1967) 2.42
An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk] [1,4]benzodiazepin-2 (1H)-one and -thione derivatives. Proc Natl Acad Sci U S A (1991) 2.37
A new virus cultivated only in organ cultures of human ciliated epithelium. Arch Gesamte Virusforsch (1966) 2.34
Common colds on Tristan da Cunha. J Hyg (Lond) (1971) 2.34
The clinical pharmacokinetics of itraconazole: an overview. Mycoses (1989) 2.27
New aspects of liposomes. Biochim Biophys Acta (1976) 2.27
A virus from epidemic vomiting disease. Br Med J (1972) 2.26
Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother (2012) 2.26
Organ cultures in virology. Prog Med Virol (1969) 2.21
Isolation of rhinoviruses and coronaviruses from 38 colds in adults. J Med Virol (1980) 2.21
Improvements in a method of growing respiratory viruses in organ cultures. Br J Exp Pathol (1967) 2.13
Some improved techniques for the study of rhinoviruses using HeLa cells. Arch Gesamte Virusforsch (1968) 2.13
Coronaviridae: second report. Intervirology (1978) 2.05
The growth of some myxoviruses in organ cultures. Br J Exp Pathol (1965) 2.05
Cultivation of viruses from a high proportion of patients with colds. Lancet (1966) 2.04
Live influenza B vaccine in volunteers. A report to the Medical Research Council by their Committee on Influenza and Other Respiratory Virus Vaccines. J Hyg (Lond) (1969) 2.02
Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob Agents Chemother (2001) 2.00
Negative life events, perceived stress, negative affect, and susceptibility to the common cold. J Pers Soc Psychol (1993) 1.99
Effects of a "new" human respiratory virus in volunteers. Br Med J (1967) 1.98
Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob Agents Chemother (2006) 1.97
Trial of ascorbic acid in prevention of colds. Br Med J (1967) 1.90
A year's experience of the rotavirus syndrome and its association with respiratory illness. Arch Dis Child (1979) 1.85
Experiments on the spread of colds. II. Studies in volunteers with coxsackievirus A21. J Hyg (Lond) (1965) 1.82
A comparative study of attenuated influenza viruses. Bull World Health Organ (1971) 1.81
An investigation of media for the long term storage of three respiratory viruses. Arch Gesamte Virusforsch (1974) 1.78
Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc Natl Acad Sci U S A (1993) 1.71
Toxicity of interferon. Br Med J (Clin Res Ed) (1981) 1.69
Time to detection of the growth of Mycobacterium tuberculosis in MGIT 960 for determining the early bactericidal activity of antituberculosis agents. Eur J Clin Microbiol Infect Dis (2010) 1.67
Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther (1993) 1.66
The activity of enviroxime against rhinovirus infection in man. Lancet (1981) 1.66
Letter: Rubella-specific IgM and a new inhibitor. Br Med J (1974) 1.66
Prevention of rhinovirus colds by human interferon alpha-2 from Escherichia coli. Lancet (1982) 1.66
Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. J Mol Biol (1996) 1.65
Immunity to attenuated influenza virus WRL 105 infection induced by heterologous, inactivated influenza A virus vaccines. J Hyg (Lond) (1977) 1.62
Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. Antimicrob Agents Chemother (1986) 1.60
Antiviral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model. Eur Respir J (2010) 1.59
Further trials of live influenza vaccine. Br Med J (1966) 1.58
The morphology of three previously uncharacterized human respiratory viruses that grow in organ culture. J Gen Virol (1967) 1.58
Cultivation of "difficult" viruses from patients with common colds. Br Med J (1968) 1.57
Structures of poliovirus complexes with anti-viral drugs: implications for viral stability and drug design. Curr Biol (1994) 1.57
Electron microscopic observations on the entry of influenza virus into susceptible cells. J Gen Virol (1974) 1.55
Coronaviridae. Intervirology (1975) 1.55
Growth of viruses in organ cultures of intestine. Br J Exp Pathol (1970) 1.54
Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nat Struct Biol (1995) 1.53
Bioassays for itraconazole blood levels: an interlaboratory collaborative study. J Antimicrob Chemother (1999) 1.52
A TIBO derivative, R82913, is a potent inhibitor of HIV-1 reverse transcriptase with heteropolymer templates. Antiviral Res (1991) 1.51
The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur J Clin Pharmacol (1989) 1.49
A mathematical model of common-cold epidemics on Tristan da Cunha. J Hyg (Lond) (1971) 1.47
Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: serological responses and clinical reactions. J Biol Stand (1979) 1.45
Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues. Bioorg Med Chem Lett (2001) 1.44
Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol (2000) 1.43
Smoking, alcohol consumption, and susceptibility to the common cold. Am J Public Health (1993) 1.43
Sendai virus infection of rats as a convenient model of acute respiratory infection. Vet Rec (1970) 1.42
Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection. Antimicrob Agents Chemother (1992) 1.41
Multivariate analysis of human immunodeficiency virus type 1 neutralization data. J Virol (1996) 1.41
Live influenza vaccines. Lancet (1983) 1.39
The radiation dosimetry of 99Tcm-exametazime. Nucl Med Commun (1990) 1.39
Prophylaxis of influenza with a synthetic isoquinoline. Lancet (1968) 1.38
Human rhinovirus 14 complexed with antiviral compound R 61837. J Mol Biol (1991) 1.38
Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 A resolution. Structure (1995) 1.37
Picornaviridae. Intervirology (1974) 1.36
Failure of oral 4',6-dichloroflavan to protect against rhinovirus infection in man. Arch Virol (1983) 1.35
Itraconazole pharmacokinetics in the female genital tract: plasma and tissue levels in patients undergoing hysterectomy after a single dose of 200 mg itraconazole. Eur J Obstet Gynecol Reprod Biol (1986) 1.34
A comparison of WIN 51711 and R 78206 as stabilizers of poliovirus virions and procapsids. J Gen Virol (1991) 1.34
Suppression of colds in human volunteers challenged with rhinovirus by a new synthetic drug (R61837). Antimicrob Agents Chemother (1989) 1.33
A comparison of the anti-rhinoviral drug binding pocket in HRV14 and HRV1A. J Mol Biol (1993) 1.32
Antibody responses to and efficacy of an inactivated spray vaccine. Bull World Health Organ (1969) 1.29
Deficient production of leucocyte interferon (interferon-alpha) in vitro and in vivo in children with recurrent respiratory tract infections. Lancet (1981) 1.27
Prophylaxis and treatment of rhinovirus colds with zinc gluconate lozenges. J Antimicrob Chemother (1987) 1.27
Titration of tuberculin, nucleic acids and viruses by haemaggregation inhibition using a "pattern" test. Br J Exp Pathol (1967) 1.26
An epidemic of influenza on Tristan da Cunha. J Hyg (Lond) (1973) 1.26
Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother (2009) 1.25
In vitro interactions between new antitubercular drug candidates SQ109 and TMC207. Antimicrob Agents Chemother (2010) 1.25
Identification of rhinovirus stran D.C. Nature (1968) 1.24